ACUTE MYELOID LEUKEMIA (AML)
Clinical trials for ACUTE MYELOID LEUKEMIA (AML) explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA (AML) trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA (AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to boost survival in aggressive leukemia
Disease control ENROLLING_BY_INVITATIONThis study tests three different chemotherapy regimens in 450 young adults (ages 15-65) with intermediate- or high-risk acute myeloid leukemia (AML). All regimens include the experimental drug lisaftoclax plus standard chemotherapies. The main goal is to see which combination lea…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2, PHASE3 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising combo offers hope for older AML patients
Disease control OngoingThis phase 3 study tested whether adding venetoclax to azacitidine helps people with untreated acute myeloid leukemia (AML) who cannot receive standard chemotherapy. About 443 adults took part, with two-thirds receiving the drug combo and one-third getting a placebo plus azacitid…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered donor cells aim to beat blood cancer without severe side effects
Disease control OngoingThis study tests a new way to treat children and young adults with high-risk blood cancers like leukemia and lymphoma. Doctors take blood cells from a family donor, remove certain T cells that can cause a harmful immune reaction, and then transplant the modified cells. The goal i…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Could a targeted drug make stem cell transplants more effective for tough blood cancers?
Disease control OngoingThis early-phase trial is testing whether adding the drug venetoclax to standard chemotherapy before and after a bone marrow transplant can help prevent cancer from coming back in people with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or related blood…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: Jacqueline Garcia, MD • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Personalized dosing may boost immune recovery in stem cell transplants
Disease control OngoingThis study tests whether giving a personalized dose of a drug called r-ATG before a stem cell transplant helps the immune system recover faster and reduces serious side effects. It includes children and adults with acute leukemia or myelodysplastic syndrome (MDS) receiving a dono…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Shorter treatment course may ease side effects for AML patients
Disease control OngoingThis study tests a new way of giving two drugs—venetoclax and azacitidine—to adults with acute myeloid leukemia (AML) who are not healthy enough for standard chemotherapy. Instead of the usual 7 days of azacitidine, this approach uses only 5 days per cycle to try to reduce infect…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: University of Leipzig • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for AML patients: oral drug aims to keep remission going
Disease control OngoingThis study looks at how well and how safely oral azacitidine (ONUREG) works as maintenance therapy for Chinese adults with acute myeloid leukemia (AML) who are in remission after initial chemotherapy. The 44 participants cannot or choose not to have a stem cell transplant. Resear…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New triple therapy targets FLT3-Mutated leukemia in frail patients
Disease control OngoingThis study tests a combination of three drugs—gilteritinib, venetoclax, and azacitidine—in people newly diagnosed with a fast-growing form of acute myeloid leukemia (AML) that has a FLT3 gene change. Participants are older or have other health issues that prevent them from receiv…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC